Comparative Pharmacology
Head-to-head clinical analysis: DEPODUR versus LEVO DROMORAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEPODUR versus LEVO DROMORAN.
DEPODUR vs LEVO-DROMORAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Morphine sulfate extended-release liposomal injection; morphine is a full opioid agonist with relative selectivity for the mu-opioid receptor, although it can interact with other opioid receptors at higher doses. The analgesic effects are mediated by activation of mu-opioid receptors in the central nervous system, leading to modulation of pain pathways.
Levo-dromoran (levorphanol) is a potent opioid agonist primarily at mu-opioid receptors, with additional agonist activity at kappa and delta opioid receptors. It also acts as an NMDA receptor antagonist and inhibits serotonin and norepinephrine reuptake, contributing to its analgesic effects.
Epidural: 5-15 mg as a single dose (morphine sulfate 10 mg/mL extended-release liposome injection).
2 mg orally every 6-8 hours as needed for pain; 2-4 mg intramuscularly or subcutaneously every 6-8 hours; intravenous administration: 1-2 mg slowly (over 2-3 minutes) every 6-8 hours.
None Documented
None Documented
The terminal elimination half-life of morphine is approximately 2-4 hours in adults. However, DEPODUR (extended-release liposomal morphine) has a prolonged half-life due to slow release from the liposomal depot, with an effective half-life of about 12-24 hours, supporting once-daily dosing.
Terminal elimination half-life is 15-30 hours (mean 22 hours) in adults; prolonged in hepatic or renal impairment, requiring dose adjustment.
Morphine is primarily excreted renally, with approximately 90% of the dose eliminated in urine within 24 hours, mainly as morphine-3-glucuronide (M3G, ~50%), morphine-6-glucuronide (M6G, ~10%), and unchanged morphine (~10%). Fecal excretion accounts for less than 10%.
Primarily renal (approximately 60% as unchanged drug and metabolites); biliary/fecal elimination accounts for about 30%.
Category C
Category C
Opioid Analgesic
Opioid Analgesic